CoChat
Cited by 213

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?

Open access
Jung, Christoph, Kmiec, Dorota, Koepke, Lennart, Zech, Fabian, Jacob, Timo, Sparrer, Konstantin M. J., Kirchhoff, Frank · 2022 · Journal of Virology

Abstract

Emerging strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic, that show increased transmission fitness and/or immune evasion are classified as “variants of concern” (VOCs). Recently, a SARS-CoV-2 variant first identified in November 2021 in South Africa has been recognized as a fifth VOC, termed “Omicron.” What makes this VOC so alarming is the high number of changes, especially in the viral Spike protein, and accumulating evidence for increased transmission efficiency and escape from neutralizing antibodies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/jvi.02077-21

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 82

  1. 10.1038/s41577-020-00480-0 · DOI · Paper page
  2. 10.1038/d41586-021-03552-w · DOI · Paper page
  3. Grabowski F Kochańczyk M Lipniacki T. 2022. The spread of SARS-CoV-2 variant Omicron with the doubling time of 2.0–3.3 days can be explained by immune evasion. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.08.21267494v2. · DOI
  4. Bai Y Du Z Xu M Wang L Wu P Lau E Cowling BJ Meyers LA. 2021. International risk of SARS-CoV-2 Omicron variant importations originating in South Africa. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.07.21267410v1. · doi:10.1101/2021.12.07.21267410
  5. 10.2807/1560-7917.ES.2021.26.50.2101146 · DOI · Paper page
  6. 10.2807/1560-7917.ES.2021.26.50.2101147 · DOI · Paper page
  7. 10.1093/cid/ciab1041 · DOI · Paper page
  8. 10.1080/22221751.2021.2017757 · DOI · Paper page
  9. 10.1038/s41586-021-04387-1 · doi:10.1038/s41586-021-04387-1 · Paper page
  10. Basile K Rockett RJ McPhie K Fennell M Johnson-Mackinnon J Agius JE Fong W Rahman H Ko D Donavan L Hueston L Lam C Arnott A Chen SC-A Maddocks S O’Sullivan MV Dwyer DE Sintchenko V Kok J. 2021. Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.12.472252v1. · DOI
  11. Cong Z Evans JP Qu P Faraone J Zheng Y-M Carlin C Bednash JS Zhou T Lozanski G Mallampalli R Saif LJ Oltz EM Mohler P Xu K Gumina RJ Liu S-L. 2021. Neutralization and stability of SARS-CoV-2 Omicron variant. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.16.472934v1. · doi:10.1101/2021.12.16.472934v1
  12. Redd AD Nardin A Kared H Bloch EM Abel B Pekosz A Laeyendecker O Fehlings M Quinn TC Tobian AA. 2021. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. bioRxiv. 10.1101/2021.12.06.471446. · DOI
  13. Ahmed SF Quadeer AA McKay MR. 2021. SARS-CoV-2 T cell responses are expected to remain robust against Omicron. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.12.472315v1. · DOI
  14. 10.1038/s41591-022-01700-x · DOI · Paper page
  15. Keeton R Tincho MB Ngomti A Baguma R Benede N Suzuki A Khan K Cele S Bernstein M Karim F Madzorera SV Moyo-Gwete T Mennen M Skelem S Adriaanse M Mutithu D Aremu O Stek C du Bruyn E Mescht MAVD de Beer Z de Villiers TR Bodenstein A van den Berg G Mendes A Strydom A Venter M Grifoni A Weiskopf D Sette A Wilkinson RJ Bekker L-G Gray G Ueckermann V Rossouw T Boswell MT Bihman J Moore PL Sigal A Ntusi NAB Burgers WA Riou C. 2021. SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.26.21268380v1. · doi:10.1101/2021.12.26.21268380
  16. Vihta K-D Pouwels KB Peto TE Pritchard E House T Studley R Rourke E Cook D Diamond I Crook D Matthews PC Stoesser N Eyre DW Walker AS Team C-19 IS. 2022. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. medRxiv. https://www.medrxiv.org/content/10.1101/2022.01.18.22269082v1. · doi:10.1101/2022.01.18.22269082
  17. Garrett N Tapley A Andriesen J Seocharan I Fisher LH Bunts L Espy N Wallis CL Randhawa AK Ketter N Yacovone M Goga A Bekker L-G Gray GE Corey L. 2022. High rate of asymptomatic carriage associated with variant strain Omicron. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.20.21268130v2. · DOI
  18. Christensen PA Olsen RJ Long SW Snehal R Davis JJ Saavedra MO Reppond K Shyer MN Cambric J Gadd R Thakur RM Batajoo A Mangham R Pena S Trinh T Kinskey JC Williams G Olson R Gollihar J Musser JM. 2022. Signals of significantly increased vaccine breakthrough decreased hospitalization rates and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston Texas. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.30.21268560v3. · doi:10.1101/2021.12.30.21268560
  19. Bentley EG Kirby A Sharma P Kipar A Mega DF Bramwell C Penrice-Randal R Prince T Brown JC Zhou J Screaton GR Barclay WS Owen A Hiscox JA Stewart JP. 2021. SARS-CoV-2 Omicron-B.1.1.529 variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.26.474085v2. · DOI
  20. Diamond M Halfmann P Maemura T Iwatsuki-Horimoto K Iida S Kiso M Scheaffer S Darling T Joshi A Loeber S Foster S Ying B Whitener B Floyd K Ujie M Nakajima N Ito M Wright R Uraki R Li R Sakai Y Liu Y Larson D Osorio J Hernandez-Ortiz J Čiuoderis K Florek K Patel M Bateman A Odle A Wong L-Y Wang Z Edara VV Chong Z Thackray L Ueki H Yamayoshi S Imai M Perlman S Webby R Seder R Suthar M Garcia-Sastre A Schotsaert M Suzuki T Boon A Kawaoka Y Douek D Moliva J Sullivan N Gagne M Ransier A Case J Jeevan T Franks J Fabrizio T DeBeauchamp J Kercher L Seiler P Singh G Warang P Gonzalez-Reiche AS Sordillo E van Bakel H Simon V. 2022. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Res Sq. https://www.researchsquare.com/article/rs-1211792/v1. · DOI
  21. McMahan K Giffin V Tostanoski LH Chung B Siamatu M Suthar MS Halfmann P Kawaoka Y Piedra-Mora C Martinot AJ Kar S Andersen H Lewis MG Barouch DH. 2022. Reduced pathogenicity of the SARS-CoV-2 Omicron variant in hamsters. bioRxiv. https://www.biorxiv.org/content/10.1101/2022.01.02.474743v1. · doi:10.1101/2022.01.02.474743
  22. 10.1016/j.virusres.2006.01.017 · DOI · Paper page
  23. 10.1111/febs.15815 · DOI
  24. 10.1371/journal.ppat.1000896 · DOI · Paper page
  25. 10.1016/j.molcel.2020.07.027 · DOI · Paper page
  26. 10.1186/s12977-015-0148-6 · DOI
  27. Bansal K Kumar S. 2021. Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.06.471389v1. · doi:10.1101/2021.12.06.471389
  28. Nchioua R Schundner A Klute S Noettger S Zech F Koepke L Graf A Krebs S Blum H Kmiec D Frick M Kirchhoff F Sparrer KMJ. 2021. The Delta variant of SARS-CoV-2 maintains high sensitivity to interferons in human lung cells. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.11.16.468777v1. · doi:10.1101/2021.11.16.468777
  29. Karim F Moosa MYS Gosnell BI Cele S Giandhari J Pillay S Tegally H Wilkinson E San JE Msomi N Mlisana K Khan K Bernstein M Manickchund N Singh L Ramphal U COMMIT-KZN Team Hanekom W Lessells RJ Sigal A de Oliveira T. 2021. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. medRxiv. https://www.medrxiv.org/content/10.1101/2021.06.03.21258228v1. · DOI
  30. Wei C Shan K-J Wang W Zhang S Huan Q Qian W. 2021. Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.14.472632v1. · doi:10.1101/2021.12.14.472632
  31. 10.1080/01652176.2021.1921311 · DOI · Paper page
  32. Stone S Rothan HA Natekar JP Kumari P Sharma S Pathak H Arora K Aurani TT Kumar M. 2021. SARS-CoV-2 variants of concern infect the respiratory tract and induce inflammatory response in wild-type laboratory mice. bioRxiv. https://biorxiv.org/cgi/content/short/2021.09.29.462373. · doi:10.1101/2021.09.29.462373
  33. 10.1016/j.ebiom.2021.103643 · DOI · Paper page
  34. 10.1016/j.tibs.2016.05.001 · DOI · Paper page
  35. 10.3390/v13030394 · DOI
  36. 10.1128/mSphere.00408-20 · DOI · Paper page
  37. 10.1016/j.bbrc.2020.10.092 · DOI
  38. 10.1038/s41598-018-24448-2 · DOI
  39. Chen X Kim K Calabrese P Wang S Qin C Rao Y Feng P. 2021. APOBEC-mediated editing of SARS-CoV-2 genomic RNA impacts viral replication and fitness. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.18.473309v1. · DOI
  40. Song Y He X Yang W Tang T Zhang R. 2021. ADAR mediated A-to-I RNA editing affects SARS-CoV-2 characteristics and fuels its evolution. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.07.22.453345v1. · DOI
  41. 10.1128/mBio.01930-20 · DOI · Paper page
  42. 10.1016/j.celrep.2021.109126 · DOI · Paper page
  43. 10.1128/mBio.02335-21 · DOI
  44. 10.1016/j.jinf.2020.03.058 · DOI · Paper page
  45. 10.1038/s41586-020-2368-8 · DOI · Paper page
  46. 10.1016/j.isci.2021.103353 · DOI
  47. Leary S Gaudieri S Parker MD Chopra A James I Pakala S Alves E John M Lindsey BB Keeley AJ Rowland-Jones SL Swanson MS Ostrov DA Bubenik JL Das S Sidney J Sette A COVID-19 Genomics UK (COG-UK) Consortium de Silva TI Phillips E Mallal S. 2021. Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K/G204R variant in nucleocapsid: homologous recombination has potential to change SARS-CoV-2 at both protein and RNA level. bioRxiv. https://www.biorxiv.org/content/10.1101/2020.04.10.029454v4. · DOI
  48. 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
  49. 10.1038/s41586-021-03925-1 · DOI · Paper page
  50. 10.1038/s41467-021-24817-y · DOI · Paper page
  51. 10.1038/s41392-021-00558-8 · DOI · Paper page
  52. Sarkar R Lo M Saha R Dutta S Chawla-Sarkar M. 2021. S glycoprotein diversity of the Omicron variant. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.04.21267284v2. · DOI
  53. Genovese L Zaccaria M Farzan M Johnson WE Momeni B. 2021. Investigating the mutational landscape of the SARS-CoV-2 Omicron variant via ab initio quantum mechanical modeling. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.01.470748v1. · doi:10.1101/2021.12.01.470748
  54. Zahradnik J Tuekprakhon A Ginn HM Duyvesteyn HME Bahar M Khan S Avinoam O Zhou D Nutalai R Supasa P Wang B Dejnirattisai W Liu C Dijokaite A Temperton N Mongkolsapaya J Fry EE Ren J Screaton GR Schreiber G Stuart DI. 2021. Receptor binding and escape from Beta antibody responses drive Omicron-B.1.1.529 evolution. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.03.471045v1. · DOI
  55. Golcuk M Yildiz A Gur M. 2021. The Omicron variant increases the interactions of SARS-CoV-2 Spike glycoprotein with ACE2. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.06.471377v1. · doi:10.1101/2021.12.06.471377
  56. Shah M Woo HG. 2021. Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic antibodies. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.04.471200v1. · doi:10.1101/2021.12.04.471200
  57. 10.1016/j.celrep.2021.109292 · DOI · Paper page
  58. 10.1038/s41467-020-20789-7 · DOI · Paper page
  59. 10.1016/j.chom.2020.06.020 · DOI · Paper page
  60. Escalera A Gonzalez-Reiche AS Aslam S Mena I Pearl RL Laporte M Fossati A Rathnasinghe R Alshammary H van de Guchte A Bouhaddou M Kehrer T Zuliani-Alvarez L Meekins DA Balaraman V McDowell C Richt JA Bajic G Sordillo EM Krogan N Simon V Albrecht RA van Bakel H Garcia-Sastre A Aydillo T. 2021. SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.11.09.467693v1. · DOI
  61. Peacock TP Brown JC Zhou J Thakur N Newman J Kugathasan R Sukhova K Kaforou M Bailey D Barclay WS. 2022. The SARS-CoV-2 variant Omicron shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.31.474653v1. · DOI · Paper page
  62. Liu Y Liu J Johnson BA Xia H Ku Z Schindewolf C Widen SG An Z Weaver SC Menachery VD Xie X Shi P-Y. 2021. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. bioRxiv. 10.1101/2021.08.12.456173. · doi:10.1101/2021.08.12.456173
  63. Lista MJ Winstone H Wilson HD Dyer A Pickering S Galao RP Lorenzo GD Cowton VM Furnon W Suarez N Orton R Palmarini M Patel AH Snell L Nebbia G Swanson C Neil SJD. 2021. The P681H mutation in the Spike glycoprotein confers type I interferon resistance in the SARS-CoV-2 alpha (B.1.1.7) variant. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.11.09.467693v1. · DOI
  64. Wang Q Anang S Iketani S Guo Y Liu L Ho DD Sodroski JG. 2021. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.27.474288v1. · DOI
  65. Zaccaria M Genovese L Farzan M Dawson W Nakajima T Johnson W Momeni B. 2021. Anticipating future SARS-CoV-2 variants of concern through ab initio quantum mechanical modeling. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.11.25.470044v1. · DOI
  66. Mannar D Saville JW Zhu X Srivastava SS Berezuk AM Tuttle K Marquez C Sekirov I Subramaniam S. 2021. SARS-CoV-2 Omicron variant: ACE2 binding cryo-EM structure of Spike protein-ACE2 complex and antibody evasion. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.19.473380v1. · DOI
  67. 10.1016/j.bbrc.2022.01.006 · DOI
  68. 10.1038/s41392-021-00863-2 · DOI · Paper page
  69. VanBlargan LA Errico JM Halfmann P Zost SJ Crowe JE Purcell LA Kawaoka Y Corti D Fremont DH Diamond M. 2021. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.15.472828v1. · DOI
  70. Cameroni E Saliba C Bowen JE Rosen LE Culap K Pinto D Marco AD Zepeda SK di Iulio J Zatta F Kaiser H Noack J Farhat N Czudnochowski N Havenar-Daughton C Sprouse KR Dillen JR Powell AE Chen A Maher C Yin L Sun D Soriaga L Gustafsson C Franko NM Logue J Iqbal NT Mazzitelli I Geffner J Grifantini R Chu H Gori A Riva A Giannini O Ceschi A Ferrari P Franzetti-Pellanda A Garzoni C Hebner C Purcell LA Piccoli L Pizzuto MS Walls AC Telenti A Virgin HW Lanzavecchia A Veesler D Snell G Corti D. 2021. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.12.472269v1. · doi:10.1038/d41586-021-03825-4 · Paper page
  71. Aggarwal A Stella AO Walker G Akerman A Milogiannakis V Brilot F Amatayakul-Chantler S Roth N Coppola G Schofield P Jackson J Henry JY Mazigi O Langley D Lu Y Forster C McAllery S Mathivanan V Fichter C Hoppe AC Munier ML Jack H-M Cromer D Darley D Matthews G Christ D Khoury D Davenport M Rawlinson W Kelleher AD Turville S. 2021. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.14.21267772v1. · doi:10.1101/2021.12.14.21267772
  72. 10.1038/s41586-021-04005-0 · DOI · Paper page
  73. Vangeel L Chiu W Jonghe SD Maes P Slechten B Raymenants J André E Leyssen P Neyts J Jochmans D. 2022. Remdesivir molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.27.474275v2. · doi:10.1101/2021.12.27.474275
  74. Monteil V Stephanie D Klingström J Thålin C Kellner MJ Christ W Havervall S Mereiter S Knapp S Montserrat N Braunsfeld B Kozieradzki I Ali OH Hagelkruys A Stadlmann J Oostenbrink C Wirnsberger G Penninger JM Mirazimi A. 2021. Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infections. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.25.474113v1. · DOI
  75. Bojkova D Widera M Ciesek S Wass MN Michaelis M Cinatl J. 2022. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates. bioRxiv. https://www.biorxiv.org/content/10.1101/2022.01.03.474773v1. · doi:10.1101/2022.01.03.474773
  76. 10.1080/22221751.2021.2023329 · DOI · Paper page
  77. Willett BJ Grove J MacLean OA Wilkie C Logan N Lorenzo GD Furnon W Scott S Manali M Szemiel A Ashraf S Vink E Harvey W Davis C Orton R Hughes J Holland P Silva V Pascall D Puxty K da Filipe AS Yebra G Shaaban S Holden MTG Pinto RM Gunson R Templeton K Murcia P Patel AH The COVID-19 DeplOyed VaccinE (DOVE) Cohort Study investigators The COVID-19 Genomics UK (COG-UK) Consortium The G2P-UK National Virology Consortium The Evaluation of Variants Affecting Deployed COVID-19 Vaccines (EVADE) investigators Haughney J Robertson DL Palmarini M Ray S Thomson EC. 2022. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change vaccine escape and a switch in cell entry mechanism. medRxiv. https://www.medrxiv.org/content/10.1101/2022.01.03.21268111v1. · DOI
  78. 10.1093/nar/gkw1065 · DOI · Paper page
  79. 10.1038/msb.2011.75 · DOI · Paper page
  80. 10.3390/v12091006 · DOI
  81. 10.1038/s41467-021-27180-0 · DOI
  82. 10.1038/s41586-020-2772-0 · DOI · Paper page

Cited by

See all 213

Metadata

Authors
Jung, C., Kmiec, D., Koepke, L., Zech, F., Jacob, T., Sparrer, K. M. J., & Kirchhoff, F.
Venue
Journal of Virology
Published
2022-03-23
Volume
96
Issue
6
Pages
e0207721-e0207721
ISSN
  • 0022-538X (ISSN-L)
  • 1098-5514
OpenAlex
W4214767539
Cited by
213
References
22
FWCI
23.25
Type
journal article
Language
en
Open access
green
Licence
Funders
  • Bundesministerium für Bildung und Forschung (IMMUNOMOD, Restrict SARS-CoV-2)
  • Deutsche Forschungsgemeinschaft (CRC 1279, SPP 1923, KM 5/1-1)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.